Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial

• Conditions: Parkinson Disease

• Registration Number: NCT01709461
• Lead Sponsor: Rabin Medical Center

Brief Summary

the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.

Detailed Description

Not available

Study Timeline

• Status Verified: 2012-06
• Study Start: 2012-10
• Study First Submitted: 2012-10-14
• Study First Submitted QC: 2012-10-16
• Last Update Submitted: 2012-10-16
• Study First Posted: 2012-10-18
• Last Update Posted: 2012-10-18

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• subjects who are willing to contiue this treatment.
• subjects who took part in the TVP 1012/501 clinical trail.

Exclusion Criteria

• subjects who didn't take part in the TVP 1012/501 clinical trail.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Rabin Medical Center Beilinson Campus; 🇮🇱 Petach Tiqva, Hamerkaz, Israel